Axitinib INN · 1 mg & 5 mg tablets

Find the way to combatrenal cell carcinoma.

An oral tyrosine kinase inhibitor selective for VEGF receptors-1, -2 and -3, used in the therapy of advanced renal cell carcinoma.

Order Axinix How it works

Axinix

Target

VEGFR-1 · 2 · 3

Starting dose

5 mg twice daily

Interval

~12 hours apart

Indication

Advanced RCC

About Axinix

Axitinib is an oral tyrosine kinase inhibitor selective for vascular endothelial growth factor receptors -1, -2 and -3. It prevents the progression of cancer by inhibiting angiogenesis and blocking tumour growth.

Indication Dosage guidelines Prescribing info

Two strengths,one precise target

Film-coated tablets for flexible, individualised dosing — each containing Axitinib INN.

Strength

1 mg

Axinix 1

Each film coated tablet contains Axitinib INN 1 mg. Each commercial box contains 180 tablets in a bottle.

Strength

5 mg

Axinix 5

Each film coated tablet contains Axitinib INN 5 mg. Each commercial box contains 60 tablets in a bottle.

How Axinix works

Starving the tumour of its blood supply

01 / 04

Growing renal tumours release vascular endothelial growth factor (VEGF) — a signal asking nearby blood vessels to grow towards them.
VEGF docks onto VEGF receptors on the endothelial cells lining the vessel wall, switching on their tyrosine kinase activity.
Receptor signalling drives endothelial cell proliferation and survival — pathologic angiogenesis that feeds tumour growth and cancer progression.
Axitinib inhibits VEGFR-1, -2 and -3 at therapeutic plasma concentrations, inhibiting angiogenesis and blocking tumour growth.

Simplified illustration for educational purposes.

Dosage guidelines

5 mg,twice a day,12 hours apart

The recommended starting oral dose is 5 mg twice daily, with or without food, swallowed whole with a glass of water.

Full dosage guidelines

Morning dose5 mg

Evening dose5 mg

≈ 12 hours apart

Clinical profileat a glance

Scroll →

Indication

Advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

Mechanism

Inhibits receptor tyrosine kinases VEGFR-1, -2 and -3 at therapeutic plasma concentrations.

Dosing

5 mg orally twice daily, ~12 hours apart, with or without food. Swallow whole with water.

Contraindications

None.

Interactions

Avoid strong CYP3A4/5 inhibitors and inducers — and grapefruit or grapefruit juice.

Storage

Store in a cool and dry place, away from light. Keep out of the reach of children.

Global patient support program

Life-savingmedicine, withinreach

Life-saving drugs are either beyond the reach of general people or not available in many countries. Because of the patent exemptions for Bangladeshi companies, Beacon Pharmaceuticals can manufacture patented drugs — as a support to patients worldwide.